Codexis Announces New Employment Inducement Grants
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, has announced the approval of equity grants for three new employees. These grants, approved by the Compensation Committee of Codexis' Board of Directors, include:
1. Options to purchase 137,950 shares of Codexis common stock
2. 27,000 restricted stock units (RSUs)
The stock options have an exercise price equal to the closing price of Codexis' common stock on the grant date. They vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The RSUs vest in equal annual installments over three years. These equity awards are part of the company's 2024 Inducement Plan and are reported in compliance with Nasdaq Listing Rule 5635(c)4.
Codexis, Inc. (NASDAQ: CDXS), una delle principali aziende di ingegneria degli enzimi, ha annunciato l'approvazione di concessioni azionarie per tre nuovi dipendenti. Queste concessioni, approvate dal Comitato per la Compensazione del Consiglio di Amministrazione di Codexis, includono:
1. Opzioni per acquistare 137.950 azioni ordinarie di Codexis
2. 27.000 unità azionarie riservate (RSU)
Le opzioni azionarie hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di Codexis alla data di concessione. Si consolidano nel corso di quattro anni, con il 25% che si consolida al primo anniversario e il resto che si consolida mensilmente successivamente. Le RSU si consolidano in rate annuali uguali per tre anni. Queste concessioni azionarie fanno parte del Piano di Induzione 2024 dell'azienda e sono riportate in conformità con la Regola di quotazione Nasdaq 5635(c)4.
Codexis, Inc. (NASDAQ: CDXS), una de las principales empresas de ingeniería de enzimas, ha anunciado la aprobación de concesiones de acciones para tres nuevos empleados. Estas concesiones, aprobadas por el Comité de Compensación de la Junta Directiva de Codexis, incluyen:
1. Opciones para comprar 137,950 acciones ordinarias de Codexis
2. 27,000 unidades de acciones restringidas (RSUs)
Las opciones sobre acciones tienen un precio de ejercicio igual al precio de cierre de las acciones ordinarias de Codexis en la fecha de concesión. Se consolidan durante cuatro años, con un 25% consolidándose en el primer aniversario y el resto consolidándose mensualmente posteriormente. Las RSUs se consolidan en cuotas anuales iguales durante tres años. Estas concesiones de acciones son parte del Plan de Inducción 2024 de la empresa y se informan en cumplimiento de la Regla de Cotización de Nasdaq 5635(c)4.
Codexis, Inc. (NASDAQ: CDXS), 선도적인 효소 엔지니어링 회사가 세 명의 신규 직원에 대한 주식 보상을 승인했다고 발표했습니다. 이 보상은 Codexis 이사회의 보상위원회에서 승인하였으며, 내용은 다음과 같습니다:
1. Codexis 보통주 137,950주를 구매할 옵션
2. 27,000개의 제한 주식 유닛 (RSU)
주식 옵션의 행사 가격은 주식 보상일의 Codexis 보통주 종가와 동일합니다. 이 옵션은 4년에 걸쳐 행사되며, 첫 번째 기념일에 25%가 행사되고 나머지는 이후 매월 행사됩니다. RSU는 3년 동안 매년 동일한 비율로 행사됩니다. 이러한 주식 보상은 회사의 2024 유도 계획의 일환이며, Nasdaq 상장 규칙 5635(c)4를 준수하여 보고됩니다.
Codexis, Inc. (NASDAQ: CDXS), une entreprise leader dans le domaine de l'ingénierie des enzymes, a annoncé l'approbation de concessions d'actions pour trois nouveaux employés. Ces concessions, approuvées par le Comité de Rémunération du Conseil d'Administration de Codexis, comprennent :
1. Options pour acheter 137 950 actions ordinaires de Codexis
2. 27 000 unités d'actions restreintes (RSU)
Les options d'achat d'actions ont un prix d'exercice égal au prix de clôture des actions ordinaires de Codexis à la date de concession. Elles se consolident sur quatre ans, avec 25 % se consolidant au premier anniversaire et le reste se consolidant mensuellement par la suite. Les RSU se consolidant en versements annuels égaux pendant trois ans. Ces récompenses en actions font partie du Plan d'Induction 2024 de l'entreprise et sont reportées conformément à la Règle de cotation Nasdaq 5635(c)4.
Codexis, Inc. (NASDAQ: CDXS), ein führendes Unternehmen im Bereich Enzymtechnik, hat die Genehmigung von Aktienvergaben für drei neue Mitarbeiter bekannt gegeben. Diese Vergaben, die vom Vergütungsausschuss des Vorstands von Codexis genehmigt wurden, beinhalten:
1. Optionen zum Erwerb von 137.950 Stammaktien von Codexis
2. 27.000 beschränkte Aktieneinheiten (RSUs)
Die Aktienoptionen haben einen Ausübungspreis, der dem Schlusskurs der Codexis-Stammaktien am Datum der Vergabe entspricht. Sie vesten über einen Zeitraum von vier Jahren, wobei 25% am ersten Jahrestag und der Rest monatlich danach vesten. Die RSUs vesten in gleichen jährlichen Raten über drei Jahre. Diese Aktienvergaben sind Teil des Induktionsplans 2024 des Unternehmens und werden gemäß der Nasdaq-Listing-Regel 5635(c)4 berichtet.
- Codexis is actively hiring and attracting new talent
- The company has a structured equity compensation plan to incentivize employees
- None.
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 137,950 shares of Codexis common stock and (ii) 27,000 restricted stock units (RSUs) as inducement awards under the company’s 2024 Inducement Plan.
The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with Codexis through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with Codexis through the applicable vesting dates.
Codexis is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
What types of equity grants did Codexis (CDXS) announce for new employees?
How do the stock options vest for new Codexis (CDXS) employees?
What is the vesting schedule for the RSUs granted to new Codexis (CDXS) employees?
Under which plan were these equity grants made by Codexis (CDXS)?
